The $2bn takeout of Ra Pharmaceuticals provides solace for investors bemoaning the biotech market’s poor performance.
Achillion’s pivot to a next-gen project in paroxysmal nocturnal haemoglobinuria is an admission that its first attempt to compete with Alexion’s Soliris has fallen short.
Promising data in myasthenia gravis, plus a pledge to compete on price, means that Ra Pharmaceuticals’ zilucoplan could soon give Alexion a headache – and others are…
Autolus leads winners in spite of scepticism over its CAR-T, and gene therapies disappoint.
December will be a big month for Achillion's complement inhibitor and Aquestive's ALS hopes.
Swedish Orphan Biovitrum made waves yesterday by getting its rare disease asset emapalumab into the Ash late-breakers – and bagging approval soon afterwards.
Loosening of clinical requirements has encouraged more projects into the IgA nephropathy pipeline, with a steroid–based approach from Sweden’s Calliditas looking…
Annual analysis shows a new crop of biotech assets with ballooning valuations and no major partners.